Accuray and Christie InnoMed Sign Exclusive Sales Agent Agreements for Radiation Therapy Systems in Canada
Accuray and Christie InnoMed Sign Exclusive Sales Agent Agreements for Radiation Therapy Systems in Canada
March 5, 2015 at 7:13 PM EST
SUNNYVALE, Calif., March 5, 2015 -- Accuray Incorporated (Nasdaq: ARAY) and Christie InnoMed Inc. announced today that they have entered into sales agent agreements involving the CyberKnife® and TomoTherapy® System product portfolios in Canada. Under the terms of these agreements, Christie InnoMed will be the exclusive sales agent for Accuray products in this region.
"Christie InnoMed is a well-respected organization known for representing high-quality, leading-edge products. By joining forces with Christie, Accuray gains additional market coverage and increased visibility for our precise, innovative CyberKnife and TomoTherapy Systems," said Joshua H. Levine, president and chief executive officer of Accuray. "We expect that our collaboration will significantly enhance our overall selling presence in Canada, ultimately resulting in new order growth and increased patient access to our life-saving technologies moving forward."
Established in 1954, Christie InnoMed has an extensive knowledge of the Canadian radiosurgery and radiation therapy market from both a product and customer perspective. Covering the Canadian medical market for more than 60 years, they have established strong relationships with clinicians and administrators in many of the cancer centers and hospitals across the country. Under the new agreements, Christie became eligible to act as sales agent beginning on December 1, 2014. More than 16 account managers with a total of over 200 years' experience will use their industry expertise to identify and cultivate potential customers for Accuray products. The CyberKnife and TomoTherapy System product lines have set the standard of care for patients requiring radiation therapy. Both systems deliver precise doses of radiation to treat cancerous and non-cancerous tumors throughout the body.
"We look forward to a long-term partnership with Accuray and the chance to work with a company focused on providing solutions that help clinicians optimize patient care," said Dr. Michel Vachon, president and chief executive officer of Christie InnoMed Inc. "The addition of the CyberKnife and TomoTherapy Systems complement our existing product line of radiography imaging equipment. Our extensive market knowledge and deep-seated customer relationships provide us with the opportunity to have a positive impact on new order growth for these clinically proven technologies."
About Christie InnoMed
Christie InnoMed develops, distributes, integrates and supports technological products and solutions that improve performance of Canadian healthcare institutions in the areas of medical imaging and healthcare management solutions. The Christie InnoMed team helps hospitals and clinics optimize their imaging rooms and enhance their performance in terms of screening, diagnosis and management. Christie InnoMed offers customers extensive technical and clinical support to improve workflows, and optimize use of imaging technology, thereby helping deliver the best care possible.
About the CyberKnife® and TomoTherapy® Systems
The Accuray CyberKnife M6™ Series and TomoTherapy H™ Series treatment solutions cover the entire spectrum of radiation therapy needs. The CyberKnife M6 Series enables precise, high-quality, dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The CyberKnife System is the only robotic full-body radiosurgery system available today. The TomoTherapy H Series efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to Accuray's selling presence in Canada, new order growth, patient access, clinical applications, clinical results, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in Accuray's report on Form 10-K, filed on August 29, 2014, the company's report on Form 10-Q, filed on November 7, 2014, the company's report on Form 10-Q, filed on February 6, 2015, and the company's other filings with the SEC.
"Christie InnoMed is a well-respected organization known for representing high-quality, leading-edge products. By joining forces with Christie, Accuray gains additional market coverage and increased visibility for our precise, innovative CyberKnife and TomoTherapy Systems," said Joshua H. Levine, president and chief executive officer of Accuray. "We expect that our collaboration will significantly enhance our overall selling presence in Canada, ultimately resulting in new order growth and increased patient access to our life-saving technologies moving forward."
Established in 1954, Christie InnoMed has an extensive knowledge of the Canadian radiosurgery and radiation therapy market from both a product and customer perspective. Covering the Canadian medical market for more than 60 years, they have established strong relationships with clinicians and administrators in many of the cancer centers and hospitals across the country. Under the new agreements, Christie became eligible to act as sales agent beginning on December 1, 2014. More than 16 account managers with a total of over 200 years' experience will use their industry expertise to identify and cultivate potential customers for Accuray products. The CyberKnife and TomoTherapy System product lines have set the standard of care for patients requiring radiation therapy. Both systems deliver precise doses of radiation to treat cancerous and non-cancerous tumors throughout the body.
"We look forward to a long-term partnership with Accuray and the chance to work with a company focused on providing solutions that help clinicians optimize patient care," said Dr. Michel Vachon, president and chief executive officer of Christie InnoMed Inc. "The addition of the CyberKnife and TomoTherapy Systems complement our existing product line of radiography imaging equipment. Our extensive market knowledge and deep-seated customer relationships provide us with the opportunity to have a positive impact on new order growth for these clinically proven technologies."
About Christie InnoMed
Christie InnoMed develops, distributes, integrates and supports technological products and solutions that improve performance of Canadian healthcare institutions in the areas of medical imaging and healthcare management solutions. The Christie InnoMed team helps hospitals and clinics optimize their imaging rooms and enhance their performance in terms of screening, diagnosis and management. Christie InnoMed offers customers extensive technical and clinical support to improve workflows, and optimize use of imaging technology, thereby helping deliver the best care possible.
About the CyberKnife® and TomoTherapy® Systems
The Accuray CyberKnife M6™ Series and TomoTherapy H™ Series treatment solutions cover the entire spectrum of radiation therapy needs. The CyberKnife M6 Series enables precise, high-quality, dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The CyberKnife System is the only robotic full-body radiosurgery system available today. The TomoTherapy H Series efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to Accuray's selling presence in Canada, new order growth, patient access, clinical applications, clinical results, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in Accuray's report on Form 10-K, filed on August 29, 2014, the company's report on Form 10-Q, filed on November 7, 2014, the company's report on Form 10-Q, filed on February 6, 2015, and the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
For Accuray Contact:
Beth Kaplan
Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Kirsten Fallon
MSLGROUP in Boston
+1 (781) 684-0770
accuray@mslgroup.com
For Christie InnoMed Contact:
Joelle Mokbel
+1 (514) 217-6918
Jmokbel@christieinnomed.com